Small Caps Today
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Nov 20, 2025

Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?

7' read
​Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech
Nov 20, 2025

​Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech

4' read
Nov 20, 2025

TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?

Investindustrial’s bid sent TreeHouse Foods soaring as the PE firm targets its margin-expansion plan, private-label growth, strong cash flow, and discounted valuation—despite recent weak results.

7' read
Stock Market Today: ​Stocks Rise as Nvidia Earnings and Strong Jobs Report Lift Rate-Cut Hopes
Nov 20, 2025

Stock Market Today: ​Stocks Rise as Nvidia Earnings and Strong Jobs Report Lift Rate-Cut Hopes

4' read
Monro Adopts A Poison Pill After Carl Icahn’s Big Move—What’s Really Going On?
Nov 20, 2025

Monro Adopts A Poison Pill After Carl Icahn’s Big Move—What’s Really Going On?

7' read
Rumble’s Bold AI Gamble: Can A Small-Cap Video Platform Take On Big Tech With Northern Data?
Nov 19, 2025

Rumble’s Bold AI Gamble: Can A Small-Cap Video Platform Take On Big Tech With Northern Data?

7' read
Nvidia and Microsoft Join Forces in a $45 Billion Anthropic Bet as the AI Arms Race Escalates
Nov 18, 2025

Nvidia and Microsoft Join Forces in a $45 Billion Anthropic Bet as the AI Arms Race Escalates

5' read
Stock Market Today: Stocks Slide as AI Jitters and Economic Worries Build Ahead of Nvidia Earnings
Nov 18, 2025

Stock Market Today: Stocks Slide as AI Jitters and Economic Worries Build Ahead of Nvidia Earnings

5' read
PublicSquare’s Big Fintech Bet: Why Buying Tandym Could Supercharge Its Strategy!
Nov 18, 2025

PublicSquare’s Big Fintech Bet: Why Buying Tandym Could Supercharge Its Strategy!

8' read

Business & Market Movers

TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?

Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?

Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?

·Nov 20, 2025
​Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech

​Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech

·Nov 20, 2025
Stock Market Today: ​Stocks Rise as Nvidia Earnings and Strong Jobs Report Lift Rate-Cut Hopes

Stock Market Today: ​Stocks Rise as Nvidia Earnings and Strong Jobs Report Lift Rate-Cut Hopes

·Nov 20, 2025
Monro Adopts A Poison Pill After Carl Icahn’s Big Move—What’s Really Going On?

Monro Adopts A Poison Pill After Carl Icahn’s Big Move—What’s Really Going On?

·Nov 20, 2025

Rumble’s Bold AI Gamble: Can A Small-Cap Video Platform Take On Big Tech With Northern Data?

Breaking News

s
scdadmin
·Jan 30, 2024

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”

Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.

3' read
Amesite Launches Implicit Bias Training with Expert Larry Davis Jr.

Amesite Launches Implicit Bias Training with Expert Larry Davis Jr.

scdadmin·Jan 30, 2024
Stock Market Today: Mixed Signals Keep Stocks Muted

Stock Market Today: Mixed Signals Keep Stocks Muted

scdadmin·Jan 04, 2024
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger

Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger

scdadmin·Dec 15, 2023
COP28 Reshapes Oil: Navigating Energy Transition

COP28 Reshapes Oil: Navigating Energy Transition

scdadmin·Dec 14, 2023

Healthcare & Biotech

Nov 17, 2025

Day One Just Made A Bold Bet On Mersana — Here’s What It Could Mean

Day One Biopharmaceuticals is acquiring Mersana Therapeutics in a deal worth up to $285M, adding a novel B7-H4–targeting ADC and strengthening its rare-cancer pipeline alongside OJEMDA’s momentum.

8' read
SUPPER CHANGE YOUR PLANNING POWERS

Join our newsletter

Read and share new perspectives on just about any topic. Everyone’s welcome.
  • 01Create a free account
  • 02Write your story

Tech & Energy

Nov 20, 2025

​Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech

Nvidia (NVDA) delivered another blockbuster quarter on Wednesday, igniting a rally across the tech sector and reinforcing its position as the heart of the global AI buildout.

4' read